To evaluate the tolerability and immunogenicity of a booster dose of the quadrivalent meningococcal conjugate vaccine MenACWY-CRM ( Menveo , Novartis Vaccines and Diagnostics , Siena , Italy ) administered 3years after primary vaccination of adolescents enrolled in a phase 3 study with either MenACWY-CRM or MenACWY-D ( Menactra , Sanofi Pasteur , Swiftwater , Pennsylvania ) .